The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD
NCT ID: NCT00539786
Last Updated: 2014-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2006-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea
NCT01018160
Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux.
NCT04001400
Validation of a Non-invasive In-vitro Diagnostic Test (Peptest) Against Other Diagnostic Methods for GERD
NCT02456779
Trial of Proton Pump Inhibitor With Prokinetics or Placebo in Patients With Laryngopharyngeal Reflux Disease
NCT02533349
Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD
NCT01391715
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PARALLEL
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Proton pump inhibitor (rabeprazole)
Patients receives rabeprazole 20mg AM and 20mg PM for 14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* a history of gastrointestinal surgery, and a history of connective tissue disorders.
* patients with duodenal or gastric ulcers as well as other significant lesions, such as gastric cancer, esophageal cancer, or subepithelial tumors more than 1 cm observed on the upper endoscopy
20 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Poong-Lyul Rhee
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Poong-Lyul Rhee, MD. Ph.D
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center, Sungkyunkwan University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center, Sungkyunkwan University School of Medicine
Seoul, Gangnam-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006-03-071
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.